Forbes

A public health expert breaks down the details of the CDC delaying reporting of COVID-19 vaccine benefits, including study methodology issues.

Advances in nerve regeneration. Tricking AI into believing in a fake disease. Mapping the Moon. All that and more in this week’s edition of The Prototype.

Zyn nicotine pouches are FDA-authorized but can pose health risks. A doctor breaks down 7 risks from gum damage to heart effects backed by the latest research.

We don’t have an innovation problem in healthcare—we have an honesty problem. How to fix our broken culture of healthcare innovation.

GLP-1 drugs are fueling a surge in direct-to-consumer medications. But convenience may be replacing coordination—and creating new risks for patients.

The challenge for health systems now is finding an AI partner that can scale across use cases. That is the backdrop for Cleveland Clinic’s partnership with Luminai.

In this week’s edition of InnovationRx, we look at the first robotic cataract surgeries in humans, the underbelly of marketing compounded GLP-1s, and more.

A lymph node–targeted delivery platform releases antibody therapy only in tumor-like conditions, strengthening immune attack on metastatic cancer.

Should a judge decide a mother's birth plan? The case of a Florida woman in active labor exposes how post-Dobbs healthcare is eroding patient autonomy.

Medicare insolvency is not inevitable, and it’s important to question why politicians continually present it as if it is.

Cross-species research shows that RNA splicing patterns, not just gene activity, track maximum lifespan in mammals, revealing a new axis of longevity control.

The Trump administration announced a 2.48% payment increase for Medicare Advantage plans for 2027, a much bigger boost than an earlier proposal that kept rates flat.